FDA Greenlights Game-Changing Hepatitis B Drug, Offering Hope for Functional Cure

The U.S. Food and Drug Administration (FDA) has given the green light to Hibsago (bepirovirsen), a groundbreaking drug from GlaxoSmithKline (GSK) that marks the first ever antisense oligonucleotide (ASO) approved for chronic hepatitis B (CHB) and offers the potential for a 'functional cure' in some patients. This approval, announced on October 20, 2026, represents a significant shift from lifelong antiviral therapy, promising a finite treatment course for millions worldwide. For years, chronic hepatitis B patients have relied on nucleos(t)ide analogue (NA) therapy to suppress the virus, a treatment that rarely leads to the virus being completely controlled without continuous medication. Hibsago, developed in partnership with Ionis Pharmaceuticals, directly targets the genetic material of the hepatitis B virus (HBV), interrupting its ability to replicate and produce harmful proteins. Clinical data from the Phase 3 B-Well trials showed that around 19-20% of eligible adults achieved a functional cure — where both HBV DNA and Hepatitis B surface antigen (HBsAg) become undetectable for at least 24 weeks after stopping treatment — a stark improvement over the less than 1% seen with standard care alone. While this approval brings new hope, bepirovirsen comes with a Boxed Warning, the FDA most serious caution, emphasizing the need for careful monitoring of patients for potential side effects, including changes in kidney function (estimated glomerular filtration rate or eGFR) and inflammatory reactions. Eligible patients are those without cirrhosis, who have suppressed HBV DNA on existing NA therapy, and specific HBsAg levels. The focus now shifts to how widely this targeted therapy can be adopted and its long-term impact on the global CHB burden, pushing forward the long-sought goal of truly curing this persistent disease.